Drug maker Lupin has received an approval from US Foods and Drugs Administration (USFDA) to market Perindopril Erbumine tablets in strengths of 2mg, 4 mg and 8 mg.
Perindopril Erbumine is used in treatment of stage I or II hypertension and congestive heart failure; treatment of left ventricular dysfunction after myocardial infarction.
Lupin`s activities include pharmaceuticals, bulk drugs and formulations, fermentation, bio-technology, natural products and agro chemicals.
Shares of Lupin declined Rs 9.8, or 0.69%, to trade at Rs 1,402.45. The total volume of shares traded was 8,098 at the BSE (11.38 a.m., Thursday).
